FEM
GILD icon

Fulcrum Equity Management’s Gilead Sciences GILD Stock Holding History

Fulcrum Equity Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-6,600
Closed -$508K – 153
2020
Q2 		$508K Buy
+6,600
New +$506K 0.24% 72

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Fulcrum Equity Management's GILD Position: Q3 2020 in Review

Fulcrum Equity Management sold out of Gilead Sciences (GILD) in Q3 2020, closing a stake of 6,600 shares — an estimated $508K sold.

Fulcrum Equity Management first reported a position in GILD in Q2 2020 and held it in 1 quarter. The position peaked at $508K in Q2 2020. 1,538 funds tracked by Wall St. Rank hold GILD as of Q3 2020.

  • Fulcrum Equity Management reported no remaining Gilead Sciences position as of Q3 2020 after selling out during the quarter.
  • Fulcrum Equity Management sold 6,600 Gilead Sciences shares in Q3 2020, an estimated $508K.
  • Fulcrum Equity Management first reported a position in Gilead Sciences in Q2 2020 and held it in 1 quarter.
  • Fulcrum Equity Management's Gilead Sciences position peaked at $508K in Q2 2020.
  • 1,538 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2020.

Based on Fulcrum Equity Management's 13F filing for Q3 2020, filed 27 Oct 2020.